Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose ticagrelor after 1 month of dual antiplatelet therapy following PCI
ChiCTR2000033539Phase 4Not yet recruiting
- Sponsor
- Wuxi People's Hospital
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor and aspirin in coronary arteriosclerosis (2 arms), sponsored by Wuxi People's Hospital. Primary endpoints: BARC 2, 3, 5 bleeding and Major adverse cardiovascular and cerebrovascular events. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
ticagreloraspirin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2000033539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033539.